

CLAIMS

1. Use of a non-competitive anti-OX40 antibody or antigen-binding fragment thereof and an anti-TIGIT antibody or antigen binding fragment thereof in the preparation of a combination medicament for cancer treatment.

2. The use of claim 1, wherein the OX40 antibody specifically binds to human OX40 and comprises:

(i) a heavy chain variable region that comprises (a) a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 3, (b) a HCDR2 of SEQ ID NO:24, and (c) a HCDR3 of SEQ ID NO:5 and a light chain variable region that comprises: (d) a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO:25, (e) a LCDR2 of SEQ ID NO:19, and (f) a LCDR3 of SEQ ID NO:8;

(ii) a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO:3, (b) a HCDR2 of SEQ ID NO:18, and (c) a HCDR3 of SEQ ID NO:5; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO:6, (e) a LCDR2 of SEQ ID NO:19, and (f) a LCDR3 of SEQ ID NO: 8;

(iii) a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO:3, (b) a HCDR2 of SEQ ID NO:13, and (c) a HCDR3 of SEQ ID NO:5; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO:6, (e) a LCDR2 of SEQ ID NO:7, and (f) a LCDR3 of SEQ ID NO:8; or

(iv) a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO:3, (b) a HCDR2 of SEQ ID NO:4, and (c) a HCDR3 of SEQ ID NO:5; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO:6, (e) a LCDR2 of SEQ ID NO:7, and (f) a LCDR3 of SEQ ID NO:8 in combination with an anti-TIGIT antibody or antigen binding fragment thereof.

3. The use of claim 1, wherein the OX40 antibody or antigen-binding comprises:

(i) a heavy chain variable region (VH) that comprises SEQ ID NO:26, and a light chain variable region (VL) that comprises SEQ ID NO: 28;

(ii) a heavy chain variable region (VH) that comprises SEQ ID NO: 20, and a light chain variable region (VL) that comprises SEQ ID NO: 22;

(iii) a heavy chain variable region (VH) that comprises SEQ ID NO: 14, and a light chain variable region (VL) that comprises SEQ ID NO: 16; or

(iv) a heavy chain variable region (VH) that comprises SEQ ID NO:9, and a light chain variable region (VL) that comprises SEQ ID NO:11.

4. The use of any one of claims 1 to 3, wherein the anti-TIGIT antibody or antigen binding fragment thereof comprises an antibody antigen binding domain which specifically binds human TIGIT, and comprises a heavy chain variable region comprising: HCDR1 of SEQ ID NO: 32, HCDR2 of SEQ ID NO: 33, and HCDR3 of SEQ ID NO:34; and a light chain variable region comprising: LCDR1 of SEQ ID NO:35, LCDR2 of SEQ ID NO: 36, and LCDR3 of SEQ ID NO: 37.

5. The use of any one of claims 1 to 3, wherein the anti-TIGIT antibody comprises an antibody antigen binding domain which specifically binds human TIGIT, and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO:39 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 41.

6. The use of anyone of claims 1 to 5, wherein the anti-OX40 antibody or antigen binding fragment is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab')₂ fragments.

7. The use of any one of claims 1 to 6, wherein the anti-TIGIT antibody or antigen binding fragment is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab')₂ fragments.

8. The use of any one of claims 1 to 7, wherein the cancer is breast cancer, colon cancer head and neck cancer, gastric cancer, kidney cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, ovarian cancer, skin cancer, mesothelioma, lymphoma, leukemia, myeloma or sarcoma.

9. The use of claim 8, wherein the breast cancer is metastatic breast cancer.

10. The use of any one of claims 1-9, wherein the treatment results in a sustained anti-cancer response in the subject after cessation of the treatment.

11. Use of a non-competitive anti-OX40 antibody or antigen-binding fragment thereof and an anti-TIGIT antibody or antigen binding fragment thereof in the preparation of a combination medicament for increasing, enhancing, or stimulating an immune response or function in a subject.

12. The use of claim 11, wherein the OX40 antibody or antigen-binding fragment thereof specifically binds to human OX40 and comprises:

(i) a heavy chain variable region that comprises (a) a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 3, (b) a HCDR2 of SEQ ID NO:24, and (c) a HCDR3 of SEQ ID NO:5 and a light chain variable region that comprises: (d) a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO:25, (e) a LCDR2 of SEQ ID NO:19, and (f) a LCDR3 of SEQ ID NO:8;

(ii) a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO:3, (b) a HCDR2 of SEQ ID NO:18, and (c) a HCDR3 of SEQ ID NO:5; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO:6, (e) a LCDR2 of SEQ ID NO:19, and (f) a LCDR3 of SEQ ID NO: 8;

(iii) a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO:3, (b) a HCDR2 of SEQ ID NO:13, and (c) a HCDR3 of SEQ ID NO:5; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO:6, (e) a LCDR2 of SEQ ID NO:7, and (f) a LCDR3 of SEQ ID NO:8; or

(iv) a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO:3, (b) a HCDR2 of SEQ ID NO:4, and (c) a HCDR3 of SEQ ID NO:5; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO:6, (e) a LCDR2 of SEQ ID NO:7, and (f) a LCDR3 of SEQ ID NO:8 in combination with an anti-TIGIT antibody or antigen binding fragment thereof.

13. The use of claim 11, wherein the OX40 antibody or antigen-binding comprises:

(i) a heavy chain variable region (VH) that comprises SEQ ID NO:26, and a light chain variable region (VL) that comprises SEQ ID NO: 28;

(ii) a heavy chain variable region (VH) that comprises SEQ ID NO: 20, and a light chain variable region (VL) that comprises SEQ ID NO: 22;

(iii) a heavy chain variable region (VH) that comprises SEQ ID NO: 14, and a light chain variable region (VL) that comprises SEQ ID NO: 16; or

(iv) a heavy chain variable region (VH) that comprises SEQ ID NO:9, and a light chain variable region (VL) that comprises SEQ ID NO:11.

14. The use of any one of claims 11 to 13, wherein the anti-TIGIT antibody or antigen binding fragment thereof comprises an antibody antigen binding domain which specifically binds human TIGIT, and comprises a heavy chain variable region comprising: HCDR1 of SEQ ID NO: 32, HCDR2 of SEQ ID NO: 33, and HCDR3 of SEQ ID NO:34; and a light chain variable region comprising: LCDR1 of SEQ ID NO:35, LCDR2 of SEQ ID NO: 36, and LCDR3 of SEQ ID NO: 37.

15. The use of any one of claims 11 to 13, wherein the anti-TIGIT antibody or antigen binding fragment thereof comprises an antibody antigen binding domain which specifically binds human TIGIT, and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO:39 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 41.

16. The use of any one of claims 11 to 15, wherein the anti-OX40 antibody or antigen binding fragment thereof is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab')₂ fragments.

17. The use of any one of claims 11 to 16, wherein the anti-TIGIT antibody or antigen binding fragment thereof is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab')₂ fragments.

18. The use of any one of claims 11 to 17, wherein stimulating an immune response is associated with T cells or NK cells.

19. The use of claim 18, wherein stimulating an immune response is characterized by increased responsiveness to antigenic stimulation.

20. The use of claim 18, wherein the T cells or NK cells have increased cytokine secretion, proliferation, or cytolytic activity.
21. The use of any one of claims 18-20, wherein the T cells are CD4⁺ and CD8⁺ T cells.
22. The use of any one of claims 11-21, wherein the combination medicament is to be administered to the subject and administration results in a sustained immune response in the subject after cessation of the treatment.